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Abstract
A challenge for hepatitis C virus (HCV) vaccine development is to define epitopes that are able to elicit protective antibodies
against this highly diverse virus. The E2 glycoprotein region located at residues 412–423 is conserved and antibodies to
412–423 have broadly neutralizing activities. However, an adaptive mutation, N417S, is associated with a glycan shift in a
variant that cannot be neutralized by a murine but by human monoclonal antibodies (HMAbs) against 412–423. To
determine whether HCV escapes from these antibodies, we analyzed variants that emerged when cell culture infectious HCV
virions (HCVcc) were passaged under increasing concentrations of a specific HMAb, HC33.1. Multiple nonrandom escape
pathways were identified. Two pathways occurred in the context of an N-glycan shift mutation at N417T. At low antibody
concentrations, substitutions of two residues outside of the epitope, N434D and K610R, led to variants having improved in
vitro viral fitness and reduced sensitivity to HC33.1 binding and neutralization. At moderate concentrations, a S419N
mutation occurred within 412–423 in escape variants that have greatly reduced sensitivity to HC33.1 but compromised viral
fitness. Importantly, the variants generated from these pathways differed in their stability. N434D and K610R-associated
variants were stable and became dominant as the virions were passaged. The S419N mutation reverted back to N419S when
immune pressure was reduced by removing HC33.1. At high antibody concentrations, a mutation at L413I was observed in
variants that were resistant to HC33.1 neutralization. Collectively, the combination of multiple escape pathways enabled the
virus to persist under a wide range of antibody concentrations. Moreover, these findings pose a different challenge to
vaccine development beyond the identification of highly conserved epitopes. It will be necessary for a vaccine to induce
high potency antibodies that prevent the formation of escape variants, which can co-exist with lower potency or levels of
neutralizing activities.
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Introduction
Infection with hepatitis C virus (HCV) is a leading cause of
chronic hepatitis, cirrhosis and hepatocellular carcinoma. The
World Health Organization estimates an annual increase in the
global burden by 3–4 million new infections [1]. Encouragingly for
patients, advances in in vitro and in vivo HCV infection systems
and increased understanding of HCV virology have led to the
development of many promising HCV-specific direct acting
antivirals (DAA) [2–6]. However, the high costs of DAA will limit
their access to the large majority of HCV infected patients living in
countries with limited resources. There is clearly a need for a
preventive HCV vaccine. Humoral immunity is the primary
correlate of protection for most preventive vaccines, as shown for
smallpox and other DNA viruses. For HCV, cumulative evidence
supports the importance of virus neutralizing antibodies to
facilitate clearance. Chimpanzee studies showed that protection
from an infectious HCV inoculum is correlated with HCV-specific
antibody titers blocking infection of target cells with pseudotyped
retroviral particles expressing HCV E1E2 glycoproteins (HCVpp)
[7]. Neutralizing antibody response measured via HCVpp has
been associated with control of infection in single source outbreaks
of acute HCV infections [8,9], and in a study of active injection
drug users (IDUs) [10]. While only 25% of IDUs in this study
cleared primary HCV infection, 83% cleared subsequent re-
infection episodes, and clearance was associated with cross-
reactive neutralizing antibodies. In addition, antibodies to HCV
E2 prevent infection in a human liver-mouse chimeric model
[11,12]. Finally, an immunocompetent humanized mouse model
for HCV exhibited a robust antibody response to a recombinant
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vaccinia virus expressing HCV proteins that protected against an
infectious HCV challenge in some animals that correlated with the
serum level of E2 antibodies [13]. A key challenge for vaccine
design is to overcome the genetic diversity of the virus. This will
require information on conserved epitopes mediating virus
neutralization and on the mechanisms of HCV escape from the
humoral immune response.
HCV is a positive-strand RNA virus encoding a polyprotein
that undergoes proteolytic cleavage to 10 polypeptides, each with
distinct functions. The two envelope glycoproteins, E1 and E2,
form a heterodimer that mediates viral entry [14–16] through
interactions with cellular receptors (reviewed in [17]), and are the
natural targets for neutralizing antibodies. Both proteins are highly
glycosylated that partly shields the virus from neutralizing
antibodies [18–21]. The genes encoding E1 and E2 are the most
variable in the HCV genome. The hypervariable region one
(HVR1) in E2 is immunodominant and infected individuals
develop isolate-specific neutralizing antibodies against this region
throughout the course of their infections [22,23]. These antibodies
provide little protection since the HVR1 sequence continuously
evolves in response to pressure exerted by HVR1-specific
neutralizing antibodies leading to viral escape [23,24]. An effective
HCV vaccine will need to include conserved epitopes that are able
to elicit broadly neutralizing antibodies. Much effort has been
devoted to the identification of conserved regions mediating virus
neutralization through the isolation and characterization of
human monoclonal antibodies (HMAbs) from the B cells of
HCV-infected individuals and of murine monoclonal antibodies
from recombinant E2 glycoprotein immunized mice. The focus
has been primarily on E2 since this viral structure interacts with
HCV co-receptors and is more immunogenic than E1. Studies
with HMAbs to E2 have led to the delineation of at least six
distinct clusters of overlapping linear and nonlinear epitopes,
designated as antigenic domains A-E [25–28]. Many of these
HMAbs from different laboratories are to overlapping epitopes,
which can be grouped in one cluster, antigenic domain B. Of
concern, some domain B antibodies do not neutralize all HCV
genotypes, which is indicative of escape [29]. Single amino acid
substitutions also can lead to viral escape with other domain B
antibodies [30,31], similar to escape from antibodies against the
HVR1 [24]. There are three patterns of viral escape that are
observed when infectious cell culture virions (HCVcc) are grown
in the presence of neutralizing domain B antibodies [32]. Of the
three tested domain B HMAbs, one led to escape mutant viruses
without affecting in vitro viral fitness; a second led to escape but
with compromised viral fitness; and a third led to complete virus
elimination at a critical antibody concentration without escape
mutants. Sequence analysis of escape mutants revealed a
conserved region, amino acid (aa) 529–535, and a region, aa
425–443, on E2 that appears to be associated with escape
mutations [32].
Immediately downstream of HVR1 is a cluster of overlapping
linear epitopes that are highly conserved across all HCV genotypes
and subtypes, encompassing aa 412–423, but are of low
immunogenicity in population studies [33,34]. A number of
broadly neutralizing monoclonal antibodies targeting this region
have been isolated from experimentally immunized mice [16,35–
37] and a human monoclonal antibody, designated as HCV1, in a
transgenic mouse [38]. Their precise contact residues have been
resolved by direct crystal structure of E2 peptides in complex with
two of these antibodies, AP33 and HCV1 [39–41]. Other studies
have also established that this region is involved in virus binding to
the HCV co-receptor, CD81 [37,42], which explains why this
region is highly conserved in order to preserve essential viral
functions. Thus, antibodies to this region have held great promise
for immunotherapy and vaccine development. However, the Asn
at 417 is an N-linked glycosylation site that shields this conserved
region from being fully exposed to neutralizing antibodies by
reducing epitope access [18–21]. An adaptive mutation N417S
that leads to a glycan shift upstream to N415 blocks virus
neutralization by AP33 and HCV1 [43–45]. The N-glycan shift at
N417 occurs frequently in passaged HCVcc. The shift occurs
in the absence of selection by neutralizing antibodies targeting
this region, in the presence of neutralizing antibodies targeting
different regions or in the presence of a non-HCV HMAb
[28,32].
We recently isolated a panel of HMAbs to aa 412–423 [25].
Surprisingly, cell culture adapted 2a JFH1 HCVcc, containing
mostly glycan shifted HCVcc at N417S and a minor population
of wild-type (wt) HCVcc, displayed an increased sensitivity to
neutralization by these HMAbs, in contrast to the lack of
neutralization by a murine monoclonal antibody. This raised
questions whether and how HCV can escape from human
antibodies directed against aa 412–423, particularly because the
mutation leading to an N-glycan shift from 417 to 415 does not
lead to viral escape, but to an increase in sensitivity to these
antibodies. This report addresses these questions by assessing
viral evolution in the presence of a HMAb against aa 412–423,
designated as HC33.1. Sequence analyses of variants obtained at
different time points when 2a HCVcc was co-cultured with
HC33.1, from low to high antibody concentrations, revealed
multiple patterns of mutations. At low antibody concentrations,
mutations occurred outside of aa 412–423 in combination with
an N-glycan shift mutation at N417T. These variants exhibited
improved viral fitness and reduced sensitivity to HC33.1 binding
and neutralization. At moderate antibody concentrations, a
mutation was observed within the conserved aa 412–423 region
at residue 419 in escape variants having compromised fitness and
greater reduction in sensitivity to HC33.1. Interestingly, when
HC33.1 was removed, the 419 mutation-associated variants
rapidly disappeared and the variants that emerged contained the
wild-type residue at this position. At high antibody concentra-
tions, a mutation at 413 was observed in variants that were
completely resistant to HC33.1 neutralization. Taken together,
multiple pathways are involved in viral escape from a single
antibody that appear to be concentration dependent, and
associated with and without compromised in vitro viral fitness
in escape variants.
Author Summary
An effective hepatitis C virus (HCV) vaccine will require
information on epitopes that are responsible for protective
antibodies against this highly diverse virus. A region
known to be highly conserved and responsible for broadly
neutralizing antibodies is located on the E2 glycoprotein at
412–423. To test whether HCV can escape from human
antibodies against this region, infectious virus was
passaged in culture in increasing concentrations of a
human monoclonal antibody to 412–423. Multiple path-
ways of viral escape were identified at different levels of
antibody concentrations. Some of the escape virions were
stable and were more robust than wild-type virus. Other
escape virions were unstable and had compromised in
vitro viral fitness. Collectively, these findings underscore
the difficulties in HCV vaccine development and the need
to induce high potency antibodies not associated with
viral escape.
Viral Escape from a Human Antibody to a Conserved Region on HCV E2
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Results
HMAbs and a mouse monoclonal antibody to aa 412–423
have different neutralization profiles
Employing AP33 as the prototype antibody to this region
[16,35–37,43], epitope mapping of this and three HMAbs to aa
412–423, HC33.1, HC33.4 and HC33.8 (designated as antigenic
domain E), revealed shared contact residues at L413, G418 and
W420, as determined by ,20% binding to a panel of alanine
substitution H77C E1E2 mutants (Fig. 1A) [25]. No contact
residues were identified between aa 425–443 with the HC33
HMAbs (data not shown). They differed at residue 415, in which a
N415A mutation led to AP33 binding reduction of 73% and the
HC33 HMAbs having no binding reduction. To define the
different neutralization profiles of AP33 and HC33 HMAbs
against glycan shifted HCVcc variants, JFH1 E1E2 plasmids were
constructed to contain N417S or N417T. The N417S mutation
has been shown to be an adaptive mutation [45] and the N417T
change was observed in the HC33.1 selection studies (see below).
Both substitutions resulted in an N-glycan shift from residue 417 to
N415. Wild type and variant HCVcc bearing N417S or N417T
were produced, and dose-dependent neutralization was measured
with AP33 and the three antigenic domain E HMAbs (Fig. 1B–
1D). AP33 and HC33.1 neutralized wt HCVcc, which was poorly
neutralized by HC33.4 and HC33.8 (Fig. 1B). AP33 had a higher
potency (IC50 at 3.5 mg/ml) than HC33.1 (IC50 at 12.5 mg/ml)
(Fig. 1F). The data is consistent with previous findings of AP33
having high neutralizing potencies against different HCV geno-
types [37]. In contrast, AP33 (up to 50 mg/ml) failed to neutralize
the N417S and N417T HCVcc variants (Fig. 1C, 1D and 1F);
whereas these variants remained sensitive to HC33.1, HC33.4 and
HC33.8. The neutralization potencies of the three domain E
antibodies significantly improved and their IC50 values ranged 0.9
to 21.2 mg/ml. HC33.1 IC50 improved by over tenfold against
both N417S/T variants compared to wt HCVcc. Of note is that
the contact residues for the HCV1 HMAb, isolated from a
transgenic mouse that was challenged with recombinant E2
proteins, are similar to the HC33 antibodies, involving 413 and
420 but with a 20 percent reduction at 418 [38]. Yet escape
variants for HCV1 have been documented to include N417T/S
mutations [44,46]. These results demonstrate the difference
between previously isolated antibodies to aa 412–423 and the
HC33 HMAbs that are elicited in response to viral infection
undergoing an N-glycan shift from 417 to 415. Moreover, the
increased potencies of the antigenic domain E HMAbs to glycan
shifted virions confirm the importance of the N-glycan at 417 in
shielding aa 412–423 from neutralizing human antibodies [18–
21].
The relative in vitro viral fitness of N417S and N417T HCVcc
variants was compared to wt by determining the virus yield at a
low multiplicity of infection (MOI= 0.1) after 96 hours post
infection. Both N417S (4.1) and N417T (3.7) had approximately
four fold higher viral yields than wt HCVcc (Fig. 1E). Statistical
analysis found both N417S (P=,0.040) and N417T (P=,0.009)
to be significantly higher than wt HCVcc. The increased fitness is
in agreement with previous findings that the glycan shift associated
with N417S is a spontaneous adaptive mutation that confers
greater viral fitness [45]. However, the previous study found the
increase to be statistically not significant (P=,0.063; [45]). The P
values between the two sets are marginally different and within
experimental fluctuations. The findings also show that the residue
at 417 is polymorphic, N417, S417 or T417, with the variants
having advantages of greater in vitro viral fitness and resistant to
neutralization to some antibodies to this region, e.g., AP33 and
HCV1 [44–46]. But this glycan shift leads to greater susceptibility
to other human antibodies to aa 412–423, and to antigenic
domain B [45].
HCV evolution in the presence of increasing
concentration of HC33.1
Escape from antibody-mediated virus neutralization occurs by
mutations at contact residues within the cognate epitope of the
virus neutralizing antibody [28,32]. However, alanine substitution
at each of the three contact residues of HC33.1 at L413, G418 or
W420 completely abolished HCVpp infection [42], suggesting that
mutations at these contact residues probably will not be an escape
mechanism from human antibodies to aa 412–423 on E2. Either
the virus cannot escape from antigenic domain E antibodies or
that escape under immune selection pressure is by a different
pathway. This was studied by an in vitro antibody-virus co-culture
protocol that mimics the evolution of viral antigenic determinants
under immune pressure in humans. The antibody-virus co-culture
system with a 2a HCVcc isolate identified the same escape
mutation for an antigenic domain B antibody as observed in an
genotype 1a infected individual [28,30–32]. Similar findings have
been reported with other escape mutations that are the same in co-
culture studies with a different 2a HCVcc isolate and observed in
clinical studies with HCV genotype 1a infected individuals
[43,44]. Thus, we believe that antibody-virus co-culture systems
identify escape variants that are broadly applicable to other
genotypes/isolates. Extracellular JFH1 HCVcc was passaged in
the presence of HC33.1 in increasing antibody concentrations.
CBH-2, an antigenic domain B HMAb, was used as a positive
(escape) control and R04, an isotype-matched HMAb to CMV
was used as negative control. The expectation was that mutations
at contact residues within the CBH-2 epitope would appear in
escape variants from CBH-2 co-culture passaged virions. Any
mutations that appeared in the R04 passaged virions would be
considered as spontaneous mutations and would be ignored if they
appeared in the variants from HC33.1 co-culture passages. At
each passage of extracellular virus, infected cells were monitored
for virus escape by screening with a two-color indirect immuno-
fluorescence assay (IFA) that used both the test antibody, and a
second antibody that recognized virus replication regardless of a
change in envelope antigenicity (Fig. 2A) [28,32]. In this case, cells
infected with an escape variant were detected by a decrease or a
loss of specific binding by the test antibody, HC33.1, but with
retained binding by an anti-NS3 antibody. When escape was
detected, RNA from escape variants was extracted from either
cells or culture supernatants, reverse-transcribed, PCR amplified,
and subcloned. Genomic residues 1491–2579 spanning the entire
E2 coding region were sequenced from selected individual clones.
The number of clones that were sequenced and analyzed ranged
from 20 to 40 per sample. To ensure that newly released variants
were transferred successfully to the next higher antibody
concentration, repetitive passages of extracellular virions in the
supernatant occurred at the lower antibody concentration until the
percent of infected cells reached .80%. When passaged virions in
supernatant resulted in .80% infected cells, the virus titers were
usually .104 FFU/ml (data not shown) [28,32]. HCV genetic
evolution under HC33.1 selection was analyzed and displayed
after elimination of spontaneous mutations observed with R04
passaged virus (Fig. 2B and 2C). The passage numbers shown in
Fig. 2 represent the evolving viral population and those passages
having similar distribution of variants were not shown. New
variants were observed and can be roughly separated into four
phases under increasing concentrations of HC33.1. Because R04
has no effect on HCV, the concentration was raised rapidly and
Viral Escape from a Human Antibody to a Conserved Region on HCV E2
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only 1–2 passages at each antibody concentration were needed to
reach .80% infected cells. Spontaneous mutations located at
V402A, N415D, N417S and F650Y were identified (Table S1), as
previously reported, but with the addition of another mutation at
650 [28]. CBH-2 escape variants were isolated that contained the
same mutations at two contact residues at 431 and 439, as
previously reported (data not shown) [28,32].
Phase I (P0–P9)
To prepare sufficient virus stock, 2a JFH1 HCVcc was passaged
multiple times in Huh7.5 cells. The final virus stock (P0) contained
a mixture of wt (20%) and the glycan shifted N417S variant (80%).
Nearly 100% of Huh7.5 cells infected with this stock was stained
strong positive (+++) by both HC33.1 and anti-NS3 by IFA (upper
panels in Fig. 2A and 2B, P0). Similar staining was observed with a
control antigenic domain B antibody, CBH-5 [27,47] (lower
panels in Fig. 2A and 2B). Approximately 104 FFU/ml of this
stock was co-cultured initially with 0.25 mg/ml HC33.1 and
designated as P1. After several passages of extracellular virions
were collected from the supernatant, the percentage of infected
cells was checked and found to be .80%. The antibody
concentration was increased to 0.5 mg/ml and after three passages,
at P6, the percent infected cell was again .80% and stained +++
with both HC33.1 and anti-NS3. Sequence analysis of extracel-
lular virions revealed that the viral population shifted completely
back to wt HCVcc with the glycan located at N417 (Fig. 2B). The
viral population remained essentially wt for the next three
passages, P6–9, as the antibody concentration increased to
1.0 mg/ml. The N-glycan shift from 415 back to 417 was a
specific response to HC33.1 immune selection in that this change
was not observed with the positive selection control, CBH-2, nor
with the isotype-matched negative control, HMAb R04 (data not
shown). Moreover, this is consistent with the greater sensitivity of
the N417S variant to be neutralized by HC33.1 (Fig. 1B and 1C)
that resulted in the re-emergence of wt HCVcc.
Phase II (P10–P19)
When the antibody concentration increased from 1.5 to 4.5 mg/
ml HC33.1 during P10–P19, a modest decrease in HC33.1
binding from +++ to ++ was observed by IFA (as shown for P18,
Fig. 2A and 2B). CBH-5 staining by IFA remained unchanged at
+++. Sequence analysis of extracellular virions at P10 (Fig. 2B)
showed wt HCVcc decreasing to 30% and the appearance of four
new variants, with each containing single or double mutations:
N417T (40%), K610R (10%), N417S+K610R (10%) or N417T+
N434D (10%). Although an N-glycan shift at N417S or N417T
increased viral sensitivity to HC33.1 (Fig. 1B–D), the observed
variants contained predominantly N417T-associated mutations as
Figure 1. Human and mouse antibodies against amino acid 412–423 have different neutralization profiles. (A) Epitope alignment.
Epitopes of three HMAbs: HC33.1; HC33.4 and HC33.8 are compared with murine MAb AP33. Recombinant E1E2 mutant proteins were expressed in
293T cells and cell lysates were analyzed by ELISA. Individual protein expression was normalized by binding of CBH-17, an anti-HCV E2 HMAb to a
linear epitope [25,47,51]. Red indicates 0–20%, orange 21–40%, brown 41–60%, white 61–100% and green .100% binding, when the residue was
replaced by alanine, relative to binding to wt. Dose-dependent neutralization of (B) wt JFH-1 HCVcc, (C) HCVcc variant bearing N417S mutation and
(D) bearing N417T mutation were performed by SEAP reporter assay. (B, C, D) Either wt HCVcc or variant HCVcc was incubated with HC33.1 or AP33,
at concentrations ranging from 0.1 to 50 mg/ml, prior to infecting the Huh7J-20 cells. Virus infectivity levels were determined by measurement of the
SEAP activity released into the medium. (F) Antibody concentration (mg/ml) required to reach 50% neutralization (IC50) for each antibody is
summarized. (E) The effect of N417S or N417T mutation on in vitro viral fitness as measured by focus forming assay at an MOI of 0.1. (B–E) Each assay
was performed in triplicates and data are shown as percent neutralization, the mean of two experiments 6SD.
doi:10.1371/journal.ppat.1004297.g001
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single, double or triple combinations with N434D and K610R.
The following two passages, P12 and P13 (Fig. 2B), showed that wt
HCVcc declined further to 10%, while the variantN417T fluctuated
between 20–40%. The most notable viral population change was
the appearance of two new variants containing double or triple
mutations, N417T+K610R or N417T+N434D+K610R, that
replaced variantN417S+K610R and variantK610R. The triple muta-
tion containing variantN417T+N434D+K610R emerged as the domi-
nant strain from P14 to P19. At P18 and P19 (not shown), this
variant accounted for 90% of the viral population (Fig. 2B). Taken
together, it is possible that the N434D and K610R mutations
provided some degree of survival benefit to the virus in
combination with N417T and not with N417S. The N434D and
K610R mutations are outside of the HC33.1 epitope that is
located at aa 412–423 on E2. The increasing dominance of the
triple mutation variantN417T+N434D+K610R indicates that a variant
having a N417T change requires additional mutations to provide
some degree of protection from the neutralizing antibody, since
N417T alone leads to a variant that is more sensitive to
neutralization by HC33.1.
Figure 2. Viral evolution in the presence of increasing HMAb HC33.1 concentrations. (A) Dual antibody immunofluorescence staining of
Huh7.5 cells infected with JFH1 2a HCVcc during multiple passages in increasing concentration of HC33.1. IFA is shown for P0, P18, P27 and P31. HCV
E2 glycoprotein was stained with HC33.1 under which viral escape variants were selected (green, upper set of panels), or with CBH-5, a neutralizing
domain B HMAb that does not share the same epitope with HC33.1 on E2 (green, lower set of panels). Total virus-infected cells were stained with
anti-NS3 antibody labeled with Alexa-594 (red). The cells were counterstained with Hoechst nuclear stain H33342 (blue). The captured images were
superimposed (merge). (B and C) Sequence analysis of escape variants in increasing concentrations of HC33.1. Circle graph represents the change in
composition of variants from selected passages, as indicated on the top, P0–P34. Specific variants are color coded as indicated in the legend. The
table presents the corresponding HC33.1 concentration and the relative intensity in IFA binding by HC33.1. The arrow line divides the viral evolution
into four phases (Phase I–IV), based on the appearance in each phase of a variant(s) bearing a specific mutation that became dominant. Viral RNA in
the corresponding cell culture supernatants were analyzed by single colony sequencing following RT-PCR amplifications.
doi:10.1371/journal.ppat.1004297.g002
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Phase III (P20–P27)
During P20–P27 with concentrations of HC33.1 increasing
from 5 to 6.0 mg/ml, the IFA intensity for HC33.1 binding
decreased further from ++ to +, while CBH-5 staining remained
+++ (as shown for P27, Fig. 2A and 2C). Sequence analysis
showed two distinct changes. First, the triple mutation var-
iantN417T+N434D+K610R declined from 90% at P20 to 20% at P25
and eliminated at P27 (Fig. 2C). When HC33.1 increased from
5 mg/ml at P20 to 5.5 mg/ml at P21, the infected cell percentage
rapidly decreased from 90% to 10%. Over the next four passages,
this antibody concentration was maintained and the infected cell
percentage gradually increased from 10 to 90% at P25. From P26
to P27, the infected cells remained high at 90%, even though
HC33.1 was increased to 6.0 mg/ml. Second, a new mutation
developed at S419N in mainly a quadruple mutation var-
iantN417T+S419N+N434D+K610R. This variant increased from 10%
at P20 to 70% at P27 (Fig. 2C). A second variantN417T+S419N was
also detected at a lower percentage of 10% at P27. The S419N
mutation is within the HC33.1 epitope, although the residue at
419 is not a contact residue for the antibody (Fig. 1A). The
findings suggest that the antibody concentration at P20 has risen to
a level where the triple mutation variantN417T+N434D+K610R can no
longer survive. Increasing HC33.1 antibody concentrations led to
greater selection pressure that resulted in the emergence of an
S419N mutation. The location of the S419N mutation is between
two contact residues for HC33.1 located at G418 and W420. Since
W420 is also a contact residue for virus binding to CD81 [42], the
S419N could lead to variants with diminished binding by HC33.1
and diminished binding by these variants to the HCV co-receptor.
Phase IV (P28–P34)
From P27 to P29, an increase of HC33.1 from 6.0 to 6.5 mg/ml
led to the appearance of two new variants with double, L413I+
N417T (20%), and triple S395P+L413I+N417T (10%) mutations
(Fig. 2C). For the first time, IFA analysis showed some infected
cells staining positive by anti-NS3 but negative by HC33.1.
Increasing HC33.1 concentrations more rapidly at 2.5 mg/ml
increments from P29 to P30 (9.0 mg/ml) to P31 (11.5 mg/ml) led
to rapid elimination of variants with the S419N mutation from
70% of combined variantN417T+S419N+N434D+K610R and var-
iantN417T+S419N+N434D at P29 to 10% at P30, and their elimination
at P31. During these passages of extracellular virions, infected cells
remained at nearly 80% positive by anti-NS3 IFA staining but
were completely negative by HC33.1 (as shown for P31, Fig. 2A).
CBH-5 remained +++. Between P30 and P31, HC33.1 reached a
critical concentration that eliminated S419N associated variants. It
is probable that there are two contributing factors. First, repeated
passages at concentrations $10 mg/ml reduced the proportion of
S419N variants in the extracellular viral pool. Second, the L413I
associated variants are able to enter Huh7.5 cells more efficiently
leading to their rapid expansion. To confirm this possibility,
extracellular virus from P31 was passaged once more at 11.5 mg/
ml to increase virus stock and then placed in two high
concentrations of HC33.1 at 20 (P33) and 50 mg/ml (P34)
(Fig. 2C). As expected, virus infectivity remained high with nearly
90% of cells stained positive by anti-NS3 and negative by HC33.1.
Sequence analyses of P33 and P34 were identical with 90%
variantS395P+L413I+N417T and 10% variantL413I+N417T.
Mutations that are associated with progressive reduction
in HC33.1 binding and neutralization
The sensitivity of escape variants isolated at different passages
compared to the initial virus stock (consisting mainly of
variantN417S at P0) was tested in dose-dependent studies with
HC33.1 (Fig. 3A). At P18 (phase II), when the dominant variant
contained triple mutations, N417T/N434D/K610R, a modest
reduction of 40% in neutralization sensitivity was apparent only at
1 mg/ml and not at the higher antibody concentrations. At P27
(phase III), when the dominant variant contained quadruple
mutations, N417T/S419N/N434D/K610R, a more significant
reduction of 50–75% in sensitivity to HC33.1 was observed at
concentrations between 1–10 mg/ml. From P31–P34 (phase IV),
when cells infected with passaged virions no longer showed
HC33.1 binding by IFA and the dominant variant contained
S395P/L413I/N417T mutations, essentially no neutralization was
observed against passaged virus (P34) at all antibody concentra-
tions. To verify these findings, and because wt HCVcc declined
rapidly in the beginning of phase II and new variants appeared in
combination with N417T, the variantN417T was employed as the
reference virus to determine the role of mutations observed in
phase II (N434D and K610R), in phase III (S419N), and in phase
IV (L413I). The N434D and K610R mutations were engineered
with N417T in double and triple mutation bearing variants. The
S419N mutation was engineered in single and quadruple mutation
variants. For the two variants observed at P31–P34 having
mutations at L413I, with or without S395P, both were constructed
in the context of N417T. HCVcc plasmid DNA constructs were
made and their corresponding viruses were harvested following
electroporation of the viral RNA into Huh7 cells. The neutral-
ization sensitivities of these recombinant HCVcc variants were
then measured (Fig. 3B). Recombinant variantN417T/N434D (IC50
2.1 mg/ml), variantN417T/K610R (IC50 1.7 mg/ml) and var-
iantN417T/N434D/K610R (IC50 1.6 mg/ml) had nearly two times
the IC50 values as variantN417T (IC50 1.0 mg/ml). This indicated
that N434D and K610R mutations contributed to modest
decrease in neutralization sensitivity to HC33.1, although com-
bining both mutations had no additive effect. For the S419N
mutation observed in phase III, the variantN417T/S419N/N434D/
K610R showed a more substantial decrease in neutralization
sensitivity with IC50 values of 6.9 mg/ml. The variants bearing
mutation at L413I with or without the S395P mutation, observed
in phase IV, were completely resistant to HC33.1 neutralization
(.50 mg/ml). The findings with constructed HCVcc variants
collectively confirmed the results observed with passaged virions
obtained in phase II, III and IV. To assess that the drop in
HC33.1 neutralization potency is due to decrease in antibody
binding to these escape variants, binding studies against recom-
binant variant E1E2 cell lysates were performed (Fig. 3C). Binding
by HC33.1 to the N417T variant was greater than to wt JFH1,
which is consistent with greater neutralization potency against the
N417T HCVcc variant (Fig. 1B and 1D). As expected, progressive
decrease in binding was observed in the following order of
variants: N417T.N417T/N434D/K610R.N417T/S419N/
N434D/K610R. No binding was observed with either L413I/
N417T or S395P/L413I/N417T associated variants, which
is consistent with complete viral escape associated with the
L413I mutation. To confirm that the S395P mutation had
no effect on HC33.1, a variant having just S395P was tested
and no reduction in HC33.1 or AP33 binding was observed (Fig.
S1).
Effects of escape mutations on in vitro viral fitness
The aa 412–423 region is known to be highly conserved and
involved in virus binding to CD81 [42]. This implies that the
region is under functional constraints and that viral escape from
neutralizing antibodies to this region will be at least associated with
compromised in vitro viral fitness. However, escape from AP33
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occurs when there is an N-glycan shift from 417 to 415 [45]
(Fig. 1B–ID). More importantly, the escape variants bearing either
N417S or N417T mutation exhibited improved viral fitness (Fig. 1E).
A similar viral escape pattern from HCV1 has been also documented
in experimental animals and HCV infected patients [44,46]. Since the
viral escape pattern fromHC33.1 is different fromAP33, viral fitness of
the dominant variants identified in phase II, III and IVwere measured.
To avoid possible contribution of non-E1E2 mutations contributing to
fitness in passaged virus, the constructed recombinant HCVcc variants
were employed for this study. Huh7 cells were infected with each
variant HCVcc at a 0.1 MOI and the infectious virus yield at 96 hours
was determined (Fig. 3D). From phase II, the two mutations, N434D
and K610R in the context of N417T, variantN434D+N417T+K610R had a
higher virus yield compared to wt HCVcc (P=,0.003). The S419N
mutation observed in phase III in the context of N417T,
variantN417T+S419N, had nearly three-fold decrease in virus yield
compared to wt HCVcc (P=,0.017). The L413I mutation in
variantL413I+N417T and variantS395P+413I+N417T had modest reductions
in virus yield compared to N417T, but they were not significantly
higher than wt HCVcc (respective P values=,0.177 and =,0.106).
All escape variants essentially had higher or normal in vitro viral fitness
except for the variants with the S419N mutation having a
compromised viral fitness.
Stable and unstable mutations associated with
progressive escape
The S419N mutation emerged at a critical inflection point of
5 mg/ml HC33.1 (P20) and not at 4.5 mg/ml (P18) (Fig. 2C). This
raised a question whether the S419N substitution is a truly
concentration-dependent mutation. To address this possibility, the
extracellular virus pool at P18, which did not contain S419N
associated variants, was passaged 14 more times with the HC33.1
concentration remaining constant at 4.5 mg/ml (Fig. 4A). Se-
quence analysis showed that the triple mutation variantN417T/
N434D/K610R persisted as the dominate isolate with other N417T
variants, variantN417T/N434D and variantN417T, at lower percent-
ages in the viral pools and eventually not detected (as shown for
P18-3 to P18-14, Fig. 4A). The fact that the S419N mutation did
not emerge indicated that the variant containing triple mutations,
N417T+N434D+K610R, sufficiently altered HC33.1 binding and
neutralization such that the virus can persist under continuous
immune selection at this antibody concentration. When the virus
was first exposed to 5 mg/ml HC33.1 at P20, the first indication of
an S419N mutation was observed and the variantN417T/S419N/
N434D/K610R rapidly expanded over subsequent passages (Fig. 2C).
To further prove that the S419N mutation is concentration
Figure 3. Analysis of escape variants on their sensitivity to HC33.1-mediated neutralization and binding, and their effect on in vitro
viral fitness. (A) HC33.1 dose-dependent neutralization against viral pool in culture supernatants collected from P0, P18, P27 and P34 with their
respective dominant variants bearing the following mutations: N417S, N417T/N434D/K610R, N417T/S419N/N434D/K610R and S395/L413I/N417T was
performed by FFU-reduction assay. (B) Dose-dependent neutralization against recombinant HCVcc variants bearing specific mutations, as identified
in each phase of viral escape selection was performed by SEAP reporter assay. The IC50 value against each variant is tabulated in the legend. (A, B)
Each assay was performed in triplicates and data are shown as percent neutralization, the mean of two experiments 6SD. (C) HC33.1 binding to
specific variants, as identified in the legend, by ELISA. Recombinant JFH1 E1E2 wt or the indicated variant E1E2 lysate was captured by GNA in
microtiter wells. The wells were then incubated with HC33.1 at the indicated concentrations (0–150 mg/ml). Binding was detected after anti-human
IgG-labeled horseradish peroxidase. The y-axis shows the mean optical density values for triplicate wells, the mean of two experiments 6SD. (D).
Effect of specific mutations on in vitro viral fitness was determined by measuring virus yield of wt or variant HCVcc bearing the indicated mutations in
the focus forming unit assay at an MOI of 0.1. Each assay was performed in triplicates and data are shown as FFU/ml, the mean of two experiments
6SD.
doi:10.1371/journal.ppat.1004297.g003
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dependent, HC33.1 was withdrawn from and repeatedly passaged
to determine whether the S419N mutation reverted back to the wt
residue at this position. The P27 viral pool comprising 70% of
variantN417T/S419N/N434D/K610R was passaged 15 more times in
the absence of HC33.1 (Fig. 4B). Sequence analysis showed that
the variantN417T/S419N/N434D/K610R reduced from 70% to 10% in
the first 4 rounds and completely disappeared in the following
rounds. The dominant isolates at P27-8 to P27-15 were triple
mutation variantN417T/N434D/K610R. At P27-15, an N417S asso-
ciated variantN417S/N434D/K610R appeared. The pattern shows that
the induction of the S419N mutation is HC33.1 antibody
concentration dependent and occurred in the context of the triple
mutation variantN417T/N434D/K610R. It is possible that these
mutations influenced the emergence of the S419N mutation.
To determine whether the triplemutation variantN417T/N434D/K610R
is stable, the viral pool at P18, containing 70%
variantN417T/N434D/K610R, was passaged repeatedly without
HC33.1 (Fig. 4C). Sequence analysis showed that this variant
persisted. It should be noted that when HC33.1 was withdrawn
from P18 and P27 (Fig. 4B and 4C), the adaptive mutation at
N417S eventually returned and co-existed with N417T. This
provides additional proof that the N417T mutation is a specific
response to HC33.1 immune selection. The L413I mutation is
associated with stable variants (Fig. 4D). When the P34 viral pool
was passaged eight times without HC33.1, sequence analyses
remained the same throughout these passages, consisting of 90%
variantS395P/L413I/N417T and 10% variantL413I/N417T. Overall,
stable and unstable mutations were induced under antibody
pressure. The mutations at 417 and 434 are a direct response to
low antibody pressure without a cost in viral fitness. Consequently,
when antibody pressure is withdrawn, variants containing these
mutations will persist. The mutation at 419 leads to more resistant
variants having compromised fitness. When antibody pressure is
withdrawn, the virus reverts back to a wt residue at this position that
restores an improved fitness.
Discussion
These studies defined the pathways of viral escape and the
formation of quasispecies from a single neutralizing antibody
directed against a conserved region encompassing aa 412–423 on
the E2 glycoprotein that underscore the difficulty in vaccine design
for this highly variable virus. Neutralization escape occurred in a
nonrandom stepwise progression in response to the antibody
concentration and was mediated by multiple mechanisms with
relatively few amino acid changes. The mutations were at residues
within and outside of the region encompassing the epitope, and
some were associated with a N-glycan shift. Multiple variants
appeared when infectious virions were co-cultured with low
antibody concentrations that have two mutations, N434D and/or
K610R, located outside of the epitope. These variants were stable
and not associated with reduced in vitro viral fitness. Their
development exemplifies the formation of variants or quasispecies
from one antibody that contributes to viral persistence in the
presence of neutralizing antibodies. In contrast, mutations within
the region encompassing the epitope, aa 412–423, had different
effects. The N-glycan shift associated mutation at S419N reverted
to wt residue at this position when antibody selection pressure was
lowered or withdrawn. The S419N associated variants, having
compromised in vitro viral fitness, highlight the constraints on
molecular evolution within the epitope because of the essential role
of this region in HCV entry. A third mutation at a contact residue,
L413I, occurred at higher HC33.1 selection pressure that resulted
in variants completely escaping virus neutralization by this
antibody. These variants were stable and had in vitro viral fitness
similar to wt HCVcc. Although the L413I mutation was elicited in
these studies, the Leu in this position is highly conserved in patient
sequences [45]. Only 11 of 2108 curated E2 sequences of .100
bases length in the LANL Hepatitis C Virus Database, varied from
Leu at this position [48,49]. All of these variants are L413P, except
for a genotype 5a sequence from South Africa which is L413F.
Additionally, only 18 of 25629 uncurated E2 sequences deposited
in GenBank since 2009 varied from Leu at 413. Again all of these
variants were L413P, except for one each of L413Q, L413F,
L413H and L413V. The elicited L413I mutation is therefore
considered not to be found thus far in nature. Similarly, in a subset
of the 2108 LANL HCV Database sequences consisting of 1311
longer high-quality E2 sequences, Gly at 418 is highly conserved
and only two out of these 1311 sequences varied from Gly. The
Trp at 420 is absolutely conserved. Only one of the 1311
sequences contained Trp to Arg change at 420 and this is more
likely due to PCR error since the W420R mutation is not tolerated
in JFH1 HCVcc (unpublished data). The observed conservation of
Leu at 413 raises a question why the L413I mutation has not been
documented more frequently in light of our studies and because
the L413I associated variants are stable, and without compromised
fitness. One possible explanation is that HC33-like antibodies are
of low frequency [33,34] and when present are of low titers. The
low immunogenicity of aa 413–423 is possibly due to the
masking effect of HVR1 [50]. Consequently, the L413I mutation
is not necessary for HCV infection to persist in the majority
of HCV infected individuals. Another possibility is that this
mutation is strictly an in vitro virus-antibody co-culture phenom-
enon. Overall, the combination of multiple escape pathways
enables the virus to persist under a wide range of antibody
concentrations.
In previous studies with antigenic domain B antibodies, epitope
mapping by alanine scanning revealed that their cognate epitopes
were located in two discontinuous segments on E2, encompassing aa
425–443 and aa 529–535 [32,51]. The region at 529–535 is highly
conserved and under functional constraints, because these residues
participate in E2 interaction with CD81 [42]. The 425–443 region
located immediately downstream of the 412–423 region is a more
variable region and five of these residues at positions 431, 434, 435,
438 and 439 are sites of escape mutations from domain B antibody-
mediated neutralization [28,31,32]. Among the five residues,
substitutions at 431 and 439 have no negative impact on in vitro
viral fitness [28,32]. But the other three at 434, 435 and 438
adversely affect fitness by reducing virus binding to CD81 [32]. In
the current studies, partial escape from HC33.1 at low antibody
concentrations also involved the 434 residue, although this antibody
is against a linear epitope upstream of this location. A mutation at
434 reduced antibody binding and neutralization. These observa-
tions taken together outline a functional sequence organization at
the N-terminal end of E2. It consists of a conserved region at aa
412–423 that is flanked by two variable regions, the HVR1 located
at aa 383–411 and a second variable region located at 425–443.
While mutations within HVR1 are mostly in response to antibodies
directed at linear epitopes within HVR1, the 425–443 variable
region is responsible for escape from antigenic domain B antibodies
and now, antigenic domain E antibodies (as represented by
HC33.1). It is possible that the K610R mutation is indicative of a
different variable region on E2. In other studies, we found that the
C-terminal end of this 425–443 variable region, encompassing 441–
443, is actually quite conserved. These three residues form a critical
binding pocket of a cluster of overlapping epitopes, designated as
antigenic domain D [28,52]. HMAbs directed at domain D are not
likely to be associated with viral escape. Taking this into
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consideration, the variable region is more restricted to the region
encompassing aa 425–440.
The second pathway of escape involves mutations associated
with a glycan shift. Asparagine (N-) linked protein glycosylation
plays crucial roles in viral protein folding and in regulation of
protein functions that include epitope accessibility. The most
commonly used glycosylation sequon was first defined as Asn-X
aa-Ser/Thr (Xaa Pro) [53], and since this first observation, more
variable sequons have been reported (review in [54]). In the aa
412–423 sequence on E2, there are three residues, N415, N417
and S419, perfectly placed for a ‘‘glycosylation sequon’’ that allows
a glycan shift either forward (+2) or backward (22) [55–57] with
Figure 4. Dose-dependent escape variants and their stability with and without continuing immune pressure. (A) The composition of
the viral pool at P18 containing the dominant variantN417T+N434D+K610R during five additional passages at a constant concentration of 4.5 mg/ml
HC33.1. (B) The composition of the viral pool at P27 containing the dominant variantN417T+S419N+N434D+K610R during 15 additional passages after
HC33.1 was removed. (C) The composition of the viral pool at P18 containing the dominant variantN417T+N434D+K610R during 15 additional passages
after HC33.1 was removed. (D) The composition of the viral pool at P34 containing the dominant variantS395P+L413I+N417T during 8 additional passages
after HC33.1 was removed. (A–D) The identified specific variants are color coded as indicated in the legend.
doi:10.1371/journal.ppat.1004297.g004
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the N417 as the key residue. Through the studies of HCV
evolution in the presence of HC33.1, at least four escape strategies
are linked to these three residues that impact antibody access to its
epitope and affecting the neutralization potency of the antibody.
However, some of these escape mechanisms are associated with a
cost in fitness. First, Asn at the 417 position, designated as the first
N-glycan among twelve in the highly glycosylated HCV E2
glycoprotein, is highly conserved among HCV genotype and
subtype isolates [18–21]. The position of this N1 glycan appears to
have a greater negative modulating effect on HC33.1 than AP33,
with both directed at aa 412–423 (Fig. 1B–1D). This is supported
by the observed shift in viral population from predominantly
N417S in the virus stock (P0) back to a more uniform wt
population, as soon as the virus was exposed to HC33.1, albeit at a
low concentration. The reappearance of wt JFH1 HCVcc was the
first step in viral escape because wt virus is more resistant to
HC33.1 neutralization than the N417S variant (Fig. 1B and 1C).
Second, the glycan shift associated with the N417S mutation
occurs spontaneously, as observed in natural infection [44,46] and
in passaged cell culture HCVcc [45]. The N417S change is an
adaptive mutation that leads to a variant with greater in vitro viral
fitness (Fig. 2E) and is able to completely escape from AP33, but
not the HC33 antibodies to aa 412–423 (Fig. 1C). The implication
is that AP33 and the HMAb HCV1 [44–46] targeting the same
region as HC33.1 are more glycan-dependent.
Third, both Ser and Thr are believed to be equal alternative
amino acids in glycosylation sequon (Asn-Xaa-Ser/Thr). Howev-
er, the selection of Thr substitution (Asn-Xaa-Thr) is associated
with HC33.1 immune pressure and not Ser substitution (Asn-Xaa-
Ser) (Fig. 2B and 2C). The finding that N417S associated variants
began to be detected after withdrawal of HC33.1 from passaged
virus supports our analysis of a Thr substitution specifically
induced by this antibody (Fig. 4B and 4C). The reason why Asn-
Xaa-Thr was preferentially selected in the presence of antibody is
not entirely clear because N417T HCVcc and N417S HCVcc
have similar fitness and sensitivity to HC33.1 (Fig. 1). Some
studies noted that glycosylation of Asn-Xaa-Thr sequons is
approximately 40 times more efficient than that of Asn-Xaa-Ser
sequons [58,59]. In addition, the selection of Asn-Xaa-Thr over
Asn-Xaa-Ser occurred in response to an antibody directed at the
aa 412–423 region but not by neutralizing antibodies directed at
other antigenic regions. When escape studies were performed with
antigenic domain B antibodies, the N417T mutation has not been
observed [28,32]. Importantly, during viral evolution in the
presence of HC33.1, the N434D, K610R and S419N escape
mutations occurred in the context of N417T and not N417S.
Taken together, the N417T change is a specific response to
HC33.1 and not an adaptive mutation. The identification of the
N417T mutation provides additional support that the virus-
antibody co-culture studies with 2a HCVcc is applicable to escape
studies with other HCV genotypes/isolates. Clinical studies with
HMAb HCV1 in liver transplant recipients infected with genotype
1a led to escape variants having the N417T or N417S mutations
[44].
Fourth, it is possible that the S419N mutation generated a new
glycan at 419 using 22 glycosylation sequon (Thr-Xaa-Asn) [55–
57]. A shared element between N1 and S419N-associated glycans
is that the middle residue in both sequons is G418, a contact
residue for HC33.1. Antibody access to this residue will be blocked
by either glycans. The S419N glycan is more efficient than the N1
glycan in shielding the HC33.1 and resulting in a significant drop
in antibody binding and neutralization (Fig. 3A–3C). However,
the formation of the S419N glycan is associated with compromised
in vitro viral fitness, which can be attributed to this glycan being in
closer proximity to W420, a contact residue for virus binding to
CD81 [42]. The effect of S419N glycan shift in reducing HC33.1
binding explains the persistence of variants with compromised
fitness over the course of multiple passages (P20–P29) under
continuous immune selection. Furthermore, the cost in viral fitness
associated with S419N explains why the N434D mutation
occurred first in the context of N417T because the fitness of
these variants was not significantly compromised. But the ability of
this mutation to reduce HC33.1 binding was not as significant as
S419N.
The transition from nearly uniform wt virions (P6–P9) to
variants that were more able to co-exist with low levels of HC33.1
in phase II (P18) (Fig. 2B) appears to be a non-random process
during viral evolution. There were a restricted number of
mutations at a limited number of sites during sequence space
expansion (P10) and contraction (P13–P14). All four variants had a
combination of N417T, N434D and K610R mutations at P13–14
that were the same mutations in the dominant variantN417T/
N434D/K610R at P18. In this phase of viral escape, a mutation
occurred in a region that is more variable, e.g., 425–440, and not
under functional constraints. Mutations in this variable region are
more likely to be in stable variants that persist regardless of
continuous presence of neutralizing antibody (Fig. 4A) or absence
of antibody (Fig. 4C). The development of stable variants or
quasispecies that are more resistant to virus neutralization partly
explains why HCV co-exists with neutralizing antibodies during
chronic infection. While this balance between variants having
robust fitness and antibody can be maintained in repeated
passages (Fig. 4A), it can be disrupted by a slight increase in
antibody concentration. When HC33.1 reached 5 mg/ml at P20
(Fig. 2C), a quadruple mutation emerged precisely by the addition
of the S419N mutation onto the existed triple mutation variant,
without undergoing a sequence space expansion. The quadruple
mutation variant preferentially replicated over the triple mutation
variant (from P20 to P27). Although the quadruple mutation
variantN417T/S419N/N434D/K610R can co-exist at higher levels of
HC33.1 (5.0–6.0 mg/ml), viral escape is still incomplete since the
virus can be neutralized at a higher percentage at higher antibody
concentrations (Fig. 3A and 3B). This suggests that incomplete
escape is sufficient for the virus to co-exist with HC33.1.
The antibody concentration-dependent stepwise escape pattern
is suggestive of low affinity or low antibody concentration
facilitating the formation of escape variants or quasispecies. This
could be the scenario during acute HCV infection when a wide
range of lower affinity neutralizing antibodies is more likely to be
elicited. As acute infection progresses to persistent infection, a
more robust neutralizing antibody response provides immune
pressure that leads to the selection of escape variants with
compromised fitness. This in turn will contribute to a transient
reduction in viral load resulting in a reduced B cell response. The
lowering of a neutralizing antibody response leads to the release of
virions with greater fitness but potentially greater sensitivity to
virus neutralization, as observed when the S419N mutation
changed back to wt when the neutralizing antibody was removed.
This cycle may explain in part persistent viremia during chronic
HCV infection in the presence of serum neutralizing antibodies.
At the same time, our findings pose a different challenge to vaccine
development beyond the identification of highly conserved
epitopes mediating virus neutralization. It will be necessary to
induce high potency neutralizing antibodies to multiple epitopes
within 412–423 that prevent the formation of escape variants,
which can co-exist with lower potency or levels of neutralizing
activities. The fact that the aa 412–423 segment on E2 is the target
of both AP33-like and HC33.1-like antibodies increases the
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importance of this region in an effective HCV vaccine. It will be
more difficult for the virus to escape simultaneously from both sets
of these antibodies. The isolation and characterization of
neutralizing human monoclonal antibodies to HCV will further
our understanding of viral neutralization escape mechanisms that
will be necessary for vaccine design.
Materials and Methods
Ethics statement
Ethical approval was obtained from the Administrative Panel on
Human Subjects in Medical Research (protocol number 13860),
Stanford University, Stanford, California, USA. Written informed
consent was obtained from the participant.
Cell culture, antibodies, virus, and reagents
HEK-293T cells were obtained from the ATCC. Huh7 [60]
and Huh7.5 cells, generously provided by Dr. Charles Rice
(Rockefeller University), were cultured at 37uC, 5% CO2 in
DMEM (Invitrogen, Carlsbad, CA) supplemented with 10% fetal
calf serum (FCS) and 2 mM glutamine (Sigma-Aldrich Co., St.
Louis, MO). The secreted alkaline phosphatase (SEAP) reporter
cell line Huh7J-20 was described previously [61]. HMAbs
HC33.1, CBH-5, CBH-17 and HC-11 against HCV E2 have
been described previously [25,47,51]. A MAb against HCV NS3
protein was generously provided by Dr. George Luo (University of
Kentucky). JFH-1 2a virus was generously provided by Dr. Takaji
Wakita (National Institute of Infectious Diseases, Japan). Virus
stocks were produced as described in [51,62] and virus titers were
determined by a focus-forming unit assay, FFU, as described [32].
Isolation of variants escaping antibody-mediated
neutralization
JFH-1 2a HCVcc was employed in this study to determine viral
evolution under HMAb HC33.1 and performed essentially as
described [28,32]. Briefly, Huh7.5 cells (3.26104/ml) seeded
24 hrs previously in a 24-well plate were inoculated with a mixture
of HCVcc (16104 FFU) and HMAb HC33.1. The initial
concentration of the neutralizing antibody was adjusted to the
25% inhibitory concentration (0.25 mg/ml) of the antibody against
the 2a HCVcc. HMAb anti-CMV R04 was used as mock human
IgG selection. The cells were collected for analysis by indirect
immunofluorescent assay (IFA) and the extracellular virus was
harvested for virus titration, the next passage of selection, and for
viral sequence analysis. The entire process constituted one passage
of infectious virus. To ensure that minority variants have a high
probability to be passed to the next round selection, extracellular
virions were repeatedly passaged until the virus titer reached
16104 FFU/ml, which correlated to $80% infected cells. Growth
of extracellular virus was measured by FFU assay and the
emergence of escape variants was monitored weekly by two-color
confocal immunofluorescence microscopy and by staining with
HC33.1 and an anti-NS3 antibody. To assess the relationship
between emerging specific mutations and the antibody concen-
tration, selected viral supernatants were passaged in the growth
medium containing antibody at a fixed concentration or no
antibody (antibody was withdrawn from the medium) for a
number of rounds as indicated.
Viral sequencing analysis
Total RNA or viral RNA from virus-containing culture
supernatant was extracted using commercial kits (Qiagen,
Valencia, CA) and reverse transcribed to cDNA SuperScript III
reverse transcriptase (Invitrogen, Carlsbad, CA) using primer
p7rev (CCCGACCCCTGATGTGCCAAGC). The envelope
genes (E1E2) were amplified using the Expend High Fidelity
PCR system (Roche Applied Sciences, Indianapolis, IN) and
primers E1F (GGAACCTTCCTGGTTGCTCTTTCTCTAT-
CTTCC) and E2R (TGCTTCGGCCTGGCCCAACAAGAT).
The PCR products were ligated into the Topo cloning vector
(Invitrogen, Carlsbad, CA), and individual clones containing an
insert of the expected size were sequenced in both sense and
antisense strands (Elim Biopharm, Hayward, CA). Selected PCR
products were cloned into pCDNA 3.1 expression vector for
protein production in binding assay.
Virus neutralization
Neutralization against extracellular virus in cultured supernatant
from different passages was measured by FFU-reduction neutral-
ization assay as previously described [28]. The antibody concen-
tration causing 50% reductions in FFU was determined by linear
regression analysis. The percent neutralization was calculated as the
percent reduction in FFU compared with virus incubated with an
irrelevant control antibody. Neutralization against recombinant
virus variants were performed using Huh7J-20 cells, and virus
infectivity levels were determined by SEAP reporter assay, as
described previously [61]. Briefly, Huh7J-20 cells were plated out
24 hrs prior to infection at a density of 36103 per well in a 96-well
plate. Virus was pre-incubated at 37 C for 1 h with the appropriate
antibody prior to infecting the cells at an MOI of 0.1. At 3 h post-
infection, the inoculum was replaced with fresh medium and
incubated for 72 hrs. The virus infectivity levels were determined by
measurement of the SEAP activity released into the medium.
Quantitative enzyme-linked immunoassay
ELISA was performed to measure antibody binding to the wt or
mutant E2 glycoproteins, as described [28]. Briefly, microtiter plates
were prepared by coating each well with 500 ng of Galanthus
nivalis agglutinin (GNA) and blocking with 2.5% nonfat dry milk
and 2.5% normal goat serum. Lysates of cells expressing wt HCV,
mutant E1E2, or pelleted virus were captured by GNA on the plate
and later bound by a range of 0 to 150 mg/ml of HMAb. The bound
HMAb was detected by incubation with alkaline phosphatase-
conjugated goat anti-human IgG (Promega; Madison, WI), followed
by incubation with p-nitrophenyl phosphate for color development.
Absorbance was measured at 405 nm and 570 nm.
Epitope mapping
Epitope mapping was performed using alanine substitution
mutants of a defined E2 region: aa 411–424. Alanine substitution
mutants were constructed in plasmids carrying the 1a H77C E1E2
coding sequence (GenBank accession number AF009606) as
previously described [28]. All the mutations were confirmed by
DNA sequence analysis (Sequetech, Mountain View, CA) for the
desired mutation and for exclusion of unexpected residue changes
in the full-length E1E2 encoding sequence. The resulting plasmids
were transfected into HEK293T cells for transient protein
expression using the calcium-phosphate method. The mutated
constructs were designated X#Y, where # is the residue location
in H77C, X denotes the single-letter code for the H77C amino
acid, and Y denotes the altered amino acid.
Virus yield assay as a measure of in vitro viral fitness
Virus-containing supernatants were inoculated onto Huh7 cells
at a multiplicity of infection (MOI) of 0.1. The cells were seeded
24 h previously in a 24-well plate. After 3 h of incubation at 37uC
and 5% CO2, the inoculum was replaced with fresh complete
Viral Escape from a Human Antibody to a Conserved Region on HCV E2
PLOS Pathogens | www.plospathogens.org 11 August 2014 | Volume 10 | Issue 8 | e1004297
medium and incubated for an additional 96 hrs. The supernatant
fluids were then collected, and the titer of infectious virus was
assessed by the SEAP reporter assay, as described previously [61].
Site-directed mutagenesis
To evaluate contribution of mutated individual amino acid
observed during viral evolution, introduction of amino acid
change was conducted using a QuikChange II site-directed
mutagenesis kit as described previously [28,32]. All the mutations
were confirmed by DNA sequence analysis (Sequetech, Mountain
View, CA) for the desired mutation and for exclusion of
unexpected residue changes in the full-length E1E2-encoding
sequence. The mutated constructs were designated X#Y, where
# is the residue location in H77C, X denotes the single-letter code
for the H77c amino acid, and Y denotes the altered amino acid.
The exception is for the K610, where # (610) is the residue
location in JFH1 that corresponds to # (606) residue location in
H77C.
Statistical analysis
Statistical analyses were performed using unpaired Student t test
(GraphPad software), with p values,0.05 considered statistically
significant.
Bioinformatics analysis
Sequences were downloaded from the Los Alamos National
Laboratory Hepatitis C Database (http://hcv.lanl.gov/content/
index, [48,49]), which contains a set of curated sequences
deposited prior to 2009. E2 sequences deposited in GenBank
(http://www.ncbi.nlm.nih.gov) from 2009 onwards were also
retrieved. Alignments were made and viewed in MEGA6 (www.
megasoftware.net [48,49].
Supporting Information
Figure S1 Dose-dependent binding of HC33.1 to a
variant bearing S395P mutation. HC33.1 and AP33 binding
to variantS395P, by ELISA. Recombinant variant E1E2 lysate was
captured by GNA in microtiter wells. The wells were then
incubated with HC33.1 or AP33 at the indicated concentrations
(0–150 mg/ml). Binding was detected after anti-human or anti-
mouse IgG-labeled horseradish peroxidase. The y-axis shows the
mean optical density values for triplicate wells, the mean of two
experiments 6SD.
(TIF)
Table S1 Percent spontaneous mutations in the pres-
ence of R04, an isotype-matched control. R04 is an IgG1
HMAb to HCMV, employed as an isotype-matched control.
Table outlines mutations with their corresponding frequency that
were identified during different passages as the antibody-
concentration was increased to 50 mg/ml.
(TIF)
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